Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) - Equities researchers at HC Wainwright reduced their Q1 2025 earnings estimates for Tyra Biosciences in a research report issued on Monday, March 31st. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($0.56) per share for the quarter, down from their prior estimate of ($0.53). HC Wainwright has a "Buy" rating and a $30.00 price objective on the stock. The consensus estimate for Tyra Biosciences' current full-year earnings is ($1.57) per share. HC Wainwright also issued estimates for Tyra Biosciences' Q2 2025 earnings at ($0.58) EPS, Q3 2025 earnings at ($0.60) EPS, Q4 2025 earnings at ($0.63) EPS and FY2025 earnings at ($2.37) EPS.
TYRA has been the topic of several other research reports. Wedbush reiterated an "outperform" rating and issued a $30.00 target price on shares of Tyra Biosciences in a research report on Friday, March 28th. UBS Group initiated coverage on Tyra Biosciences in a report on Tuesday, January 7th. They issued a "buy" rating and a $28.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $30.83.
Read Our Latest Analysis on Tyra Biosciences
Tyra Biosciences Stock Performance
Tyra Biosciences stock traded down $0.09 during trading on Thursday, reaching $7.29. The company had a trading volume of 85,388 shares, compared to its average volume of 239,019. The firm has a market capitalization of $387.03 million, a PE ratio of -4.53 and a beta of 1.19. The firm's 50-day simple moving average is $11.55 and its 200 day simple moving average is $15.73. Tyra Biosciences has a 1-year low of $7.02 and a 1-year high of $29.60.
Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.05.
Institutional Trading of Tyra Biosciences
Several large investors have recently added to or reduced their stakes in TYRA. Alta Partners Management Company L.P. acquired a new position in shares of Tyra Biosciences during the 4th quarter valued at about $56,716,000. Boxer Capital Management LLC acquired a new position in Tyra Biosciences in the 4th quarter valued at about $28,185,000. Janus Henderson Group PLC acquired a new stake in shares of Tyra Biosciences during the 3rd quarter worth approximately $24,994,000. Farallon Capital Management LLC purchased a new stake in shares of Tyra Biosciences during the 4th quarter valued at approximately $13,914,000. Finally, Vestal Point Capital LP acquired a new position in Tyra Biosciences in the fourth quarter valued at approximately $13,761,000. 84.14% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling at Tyra Biosciences
In other news, Director Nina S. Kjellson sold 7,779 shares of the company's stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $16.29, for a total value of $126,719.91. Following the completion of the sale, the director now directly owns 447,857 shares in the company, valued at $7,295,590.53. This represents a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last quarter, insiders sold 21,998 shares of company stock worth $344,818. Insiders own 15.40% of the company's stock.
Tyra Biosciences Company Profile
(
Get Free Report)
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Further Reading
Before you consider Tyra Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tyra Biosciences wasn't on the list.
While Tyra Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
